The efficacy of some newer broad spectrum anthelmintics against third-stage larvae of Ancylostoma caninum in the mouse.
The efficacy of eight anthelmintics against Ancylostoma caninum larvae in the skeletal muscles of mice was evaluated. Levamisole (5 X 40 mg/kg), thiabendazole (5 X 400 mg/kg), oxfendazole (5 X 100 mg/kg), albendazole (5 X 100 mg/kg), flubendazole (5 X 200 mg/kg), benacil (5 X 200 mg/kg) and phenacizole (5 X 200 mg/kg) showed marked larvicidal activity (98 to 99%). Sch 18099 did not show larvicidal activity even at 5 X 400 mg/kg.
D015766:Albendazole; D000722:Ancylostoma / Q000187:drug effects*; D000724:Ancylostomiasis / Q000188:drug therapy* / Q000469:parasitology; D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D007814:Larva / Q000187:drug effects; D007978:Levamisole / Q000627:therapeutic use; D008463:Mebendazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D051379:Mice; D009132:Muscles / Q000469:parasitology; D013827:Thiabendazole / Q000627:therapeutic use
D000871:Anthelmintics; D001562:Benzimidazoles; D007978:Levamisole; D008463:Mebendazole; D015766:Albendazole; D013827:Thiabendazole; C011030:oxfendazole; C018945:flubendazole